Evidence map›Paper›PMID 28416443›Full record

ArticleNeuropharmacology2017

Astrocytes modulate thalamic sensory processing via mGlu2 receptor activation.

C S Copeland, T M Wall, R E Sims, S A Neale, E Nisenbaum, H R Parri, T E Salt

Open access · hybridAbstract read
In one paragraph

Article in Neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Enhanced mGluRCell death & disease · 2024
    Article
  5. Review
  6. Article
  7. Review
  8. Astrocytic Calcium and cAMP in Neurodegenerative Diseases.Frontiers in cellular neuroscience · 2022
    Review
  9. Article
  10. Review
  11. Review
  12. The Paradox of Astroglial CaFrontiers in cellular neuroscience · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

C S CopelandInstitute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK; St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. Electronic address: carolinecopeland@gmail.com.
T M WallEli Lilly and Company, 893 S Delaware Street, Indianapolis, IN 46285, USA. Electronic address: wall_theron_marshall@lilly.com.
R E SimsSchool of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK. Electronic address: r.e.sims@aston.ac.uk.
S A NealeNeurexpert Limited, Kemp House, 152-160 City Road, London, EC1V 2NX, UK. Electronic address: stuartneale@neurexpert.com.
E NisenbaumEli Lilly and Company, 893 S Delaware Street, Indianapolis, IN 46285, USA. Electronic address: nisenbaum_eric_s@lilly.com.
H R ParriSchool of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK. Electronic address: h.r.parri@aston.ac.uk.
T E SaltInstitute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK. Electronic address: t.salt@ucl.ac.uk.
Aston University · GBEli Lilly (United States) · USIDEXX Laboratories (France) · FRSt George's, University of London · GBUniversity College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astrocytes possess many of the same signalling molecules as neurons. However, the role of astrocytes in information processing, if any, is unknown. Using electrophysiological and imaging methods, we report the first evidence that astrocytes modulate neuronal sensory inhibition in the rodent thalamus. We found that mGlu2 receptor activity reduces inhibitory transmission from the thalamic reticular nucleus to the somatosensory ventrobasal thalamus (VB): mIPSC frequencies in VB slices were reduced by the Group II mGlu receptor agonist LY354740, an effect potentiated by mGlu2 positive allosteric modulator (PAM) LY487379 co-application (30 nM LY354740: 10.0 ± 1.6% reduction; 30 nM LY354740 & 30 μM LY487379: 34.6 ± 5.2% reduction). We then showed activation of mGlu2 receptors on astrocytes: astrocytic intracellular calcium levels were elevated by the Group II agonist, which were further potentiated upon mGlu2 PAM co-application (300 nM LY354740: ratio amplitude 0.016 ± 0.002; 300 nM LY354740 & 30 μM LY487379: ratio amplitude 0.035 ± 0.003). We then demonstrated mGlu2-dependent astrocytic disinhibition of VB neurons in vivo: VB neuronal responses to vibrissae stimulation trains were disinhibited by the Group II agonist and the mGlu2 PAM (LY354740: 156 ± 12% of control; LY487379: 144 ± 10% of control). Presence of the glial inhibitor fluorocitrate abolished the mGlu2 PAM effect (91 ± 5% of control), suggesting the mGlu2 component to the Group II effect can be attributed to activation of mGlu2 receptors localised on astrocytic processes within the VB. Gating of thalamocortical function via astrocyte activation represents a novel sensory processing mechanism. As this thalamocortical circuitry is important in discriminative processes, this demonstrates the importance of astrocytes in synaptic processes underlying attention and cognition.

Indexed as

AnimalsAnimals, NewbornAstrocytesCalciumCitratesDose-Response Relationship, DrugEnzyme InhibitorsExcitatory Amino Acid AgentsIn Vitro TechniquesIontophoresisMaleN-MethylaspartateRatsRats, Sprague-DawleySensory Receptor CellsSodium Channel Blockers2-amino-5-phosphopentanoic acidCalciumCitratesEnzyme InhibitorsExcitatory Amino Acid AgentsfluorocitrateN-MethylaspartateSodium Channel BlockersTetrodotoxinValineAstrocyteMetabotropic glutamate receptor subtype 2Synaptic inhibitionThalamic reticular nucleusThalamus

Identifiers

PMID28416443
PMCPMC5480778
OpenAlexW2606202669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.